ANGLE plc (GB:AGL) has released an update.
ANGLE plc announces the publication of a clinical study that supported the FDA’s approval of their Parsortix PC1 system for harvesting circulating tumor cells (CTCs) in metastatic breast cancer patients. The study, featuring the Parsortix system’s ability to capture CTCs without relying on the traditional epithelial marker, has been published in a high-impact medical journal. The data from this research contributed to the device’s classification as a Class II medical device and highlights its potential in improving liquid biopsy techniques.
For further insights into GB:AGL stock, check out TipRanks’ Stock Analysis page.
